Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Meg Doherty
Recipe of the Month: Turmeric Tray Bake
One afternoon at the school gates when my two boys were tucking into the snack I brought them (cheese sandwich and slices of pepper in various colours) another mum said to me: “You’re giving them RAW PEPPERS for their snacks, are you serious?!” It was almost an admonishment. Happily it didn’t put me off.
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa
Correction to: Nature Communications https://doi.org/10.1038/s41467-025-60752-y, published online 1 July 2025 In the version of this article initially published, there was an error in the values shown in Table 3 for people with HIV who have ever taken lenacapavir + cabotegravir, where the percentage of people with virologic failure was originally listed as “7% (1% − 29%) 10% (9% − 10%)”; the table is now corrected to list “0% (0% − 0%) 0% (0% − 0%)” in the HTML and PDF versions of the article.
WHO 2024 hepatitis B guidelines: an opportunity to transform care
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19
15 Mwanza M, Mbewe P, Mwale C, et al. Scaling up multi-month dispensation (MMD) of antiretroviral therapy in response to COVID-19 in Zambia. 11th International AIDS Society Conference on HIV Science; July 18–21, 2021. Facility-based modifications aimed to decongest health-care settings and reduce visits, travel, and physical interactions., 21 Rodriguez-Iantorno P, Cecchini D, Mauas R, et al.
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
Abstract Background To inform World Health Organization (WHO) global guidelines, we updated and expanded the evidence base to assess the comparative efficacy, tolerability, and safety of first-line antiretroviral therapy (ART) regimens. Methods We searched Embase, Medline and CENTRAL on 28 February 2020 to update the systematic literature review of clinical trials comparing recommended first-line ART that informed previous WHO guidelines.
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
Summary To improve virological suppression and address the emerging threat of HIV drug resistance, many low-income and middle-income countries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioning to dolutegravir as part of a more affordable and standardised antiretroviral therapy (ART). Although this transition could decrease the effect of rising NNRTI resistance and yield improved ART outcomes, it also presents new challenges.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Meg
Contact Meg, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack